A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier (PPM) CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Trial Profile

A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier (PPM) CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Avadomide (Primary)
  • Indications CNS cancer; Diffuse large B cell lymphoma; Glioblastoma; Gliosarcoma; Liver cancer; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Oligodendroglioma; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 28 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2017 Results assessing safety and preliminary efficacy in patients with Diffuse Large B-Cell Lymphoma (n=97; As of May 1, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 09 May 2017 Planned number of patients changed from 274 to 296.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top